Intercorrelation of Expression of CD56, CD117, CD33, CD20 Antigens with Survival Rates in Patients with Multiple Myeloma in Gomel Region in Belarus
The detection of immunophenotype of plasma cells is very important for diagnosis of multiple myeloma. Mechanism of appearing of different antigens on the surface of malignant plasma cells and their correlation with overall survival isn't sufficiently studied.
Haematological malignancies (leukaemias, lymphomas and myeloma) are complex cancers that are relatively common, affect all ages and have divergent outcomes. Although the symptom burden of these diseases is com...
Conditions: Non Hodgkin Lymphoma; Multiple Myeloma; Chronic Lymphocytic Leukemia; Diffuse Large B Cell Lymphoma; Mantle Cell Lymphoma; Follicular Lymphoma Interventions: Genetic: JCAR017; Genetic: JCARH125 Sponsor: Juno Therapeutics, Inc. Enrolling by invitation
d R Abstract In normal cells, aberrant oncogene expression leads to the accumulation of cytotoxic metabolites, including reactive oxygen species (ROS), which can cause oxidative DNA-damage and apoptosis as an intrinsic barrier against neoplastic disease. The c-Myc oncoprotein is overexpressed in many lymphoid cancers due to c-myc gene amplification and/or 8q24 chromosomal translocations. Intriguingly, p53 is a downstream target of c-Myc and hematological malignancies, such as adult T-cell leukemia/lymphoma (ATL), frequently contain wildtype p53 and c-Myc overexpression. We therefore hypothesized that p53-regulated...
Prognostic factors of second allogeneic stem cell transplantation (allo-SCT2) in 78 patients with relapsed AML after first transplantation were explored. Those were poor cytogenetic risk at diagnosis, circulating blast ≥ 20% at relapse, duration from first transplant to relapse
Complete molecular response (CMR) and overall survival (OS) in patients with newly diagnosed Philadelphia-positive acute lymphoblastic leukemia (Ph+ ALL) treated with front-line chemotherapy plus ponatinib versus earlier-generation tyrosine kinase inhibitors (TKIs) were compared in a meta-analysis and meta-regression. Patients treated with front-line ponatinib versus earlier-generation treatments were more likely to achieve CMR and had higher rates of 3-year OS.
Multiple myeloma (MM), characterized by malignant plasma cells in the bone marrow (BM), is consistently preceded by asymptomatic pre-malignant stage monoclonal gammopathy of undetermined significance (MGUS). These MGUS patients have an annual risk of 1% to progress to MM. Clinical, imaging and genomic (genetic and epigenetic) factors were identified, whose presence increased the risk of progression from MGUS to MM. This systematic review summarizes the currently identified clinical, imaging and genomic biomarkers, suggested to increase the progression risk or demonstrated to be differential expressed/presence between both cohorts of patients.
Identifying risk factors influencing post-HSCT relapse outcome in acute leukemia is essential. 43 patients were studied. Older age and failure to achieve CR following treatment were associated with inferior OS. Female sex, extramedullary relapse and absence of post-relapse GVHD were associated with lower CR. Absence of extramedullary relapse, treatment with DLI and occurrence of post-relapse GVHD were associated with higher NRM.
This article is protected by copyright. All rights reserved.
This article is protected by copyright. All rights reserved. PMID: 29451690 [PubMed - as supplied by publisher]
There is an increasing frequency of double-hit diffuse large B-cell lymphomas, which represent at least 4% of all diffuse large B-cell lymphoma (DLBCL).1 These double-hit lymphomas (DHLs) have been defined by the 2016 WHO classification as high-grade diffuse large B cell lymphomas with translocations involving c-myc in combination with translocations of bcl-2 and/or bcl-6.2